Ghana leads the way with approval of game-changing malaria vaccine from Oxford.

Ghana has become the first country to approve the highly effective R21/Matrix-M malaria vaccine developed at Oxford University, which has exceeded the World Health Organization's target of 75% efficacy. The vaccine has been cleared for use in children aged 5-36 months, the group at highest risk of death from malaria. However, the WHO has yet to recommend the vaccine for widespread use, and there are concerns over the amount of international funding available for it. While the vaccine is a significant milestone in the fight against malaria, it is no silver bullet, and there are important points to consider before it is rolled out for wider use.